#Gilead Sciences

The antiviral drug is the first treatment for the new coronavirus to be approved in United States.

Virtually, of course. So take a look around.

4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

Nine key findings from a survey of HIV-positive people 50 and older. Plus: A special report on aging with HIV during COVID-19.

NMAC is giving away 100 Apple iPads and Verizon internet hotspots with three months of internet access. Help us identify people in need!

A low-cost generic version of Truvada as PrEP will hit the market September 30.

The results of GLAAD’s first State of HIV Stigma Study coincide with news of a $9 million Gilead grant to fight HIV in the South.

Plus: The Elizabeth Taylor AIDS Foundation and Gilead Sciences join the collective for a virtual town hall June 25.

Safeway and other Albertsons pharmacies will also participate, allowing uninsured clients to fill PrEP prescriptions at no cost.

Results from randomized clinical trials of the antiviral drug continue to show mixed results.

Hint: Gilead Sciences donated the meds for Trump’s HIV prevention program, so that cost isn’t the issue.

Scripts and testing don’t require visits to the doc thanks to this partnership between Texas Health Action and the telemedicine portals.

Envelopes were sent to people in the pharma giant’s patient assistance program for PrEP.

Gilead Sciences provides the funds through its TRANScend initiative; Destination Tomorrow in the Bronx distributes them.

Bonus: Your donations to the Broadway Cares effort Emergency Grants for Pandemic Relief will be matched by Gilead Sciences.